Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer

Oncotarget

Volumn 6, Issue 28, 2015, Pages 26483-26493

  Barrett, Michael T ^a   Anderson, Karen S ^b   Lenkiewicz, Elizabeth ^a   Andreozzi, Mariacarla ^a   Cunliffe, Heather E ^c   Klassen, Christine L ^a   Dueck, Amylou C ^a   McCullough, Ann E ^a   Reddy, Srikanth K ^d   Ramanathan, Ramesh K ^a   Northfelt, Donald W ^a   Pockaj, Barbara A ^a  

^a MAYO CLINIC   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d VANDERBILT UNIVERSITY   (United States)

Author keywords

9p24.1 amplicon; Flow sorting; JAK2; PD L1; Triple negative breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; JANUS KINASE 2; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; CD274 PROTEIN, HUMAN; JAK2 PROTEIN, HUMAN; PDCD1LG2 PROTEIN, HUMAN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; AMPLICON; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CHROMOSOME 9P; COLON CARCINOMA; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA MICROARRAY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE LOCUS; GENE TARGETING; GENOME ANALYSIS; GLIOBLASTOMA; HER2+ BREAST CANCER; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN GENOME; HUMAN TISSUE; JAK2 GENE; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PD L1 GENE; PD L2 GENE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST CANCER; CHROMOSOME 9; COLORECTAL TUMOR; COMPARATIVE STUDY; ENZYMOLOGY; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; PHENOTYPE; TIME FACTOR; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; UPREGULATION;

ADULT; AGED; ANTIGENS, CD274; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CHROMOSOMES, HUMAN, PAIR 9; COLORECTAL NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; GLIOBLASTOMA; HUMANS; JANUS KINASE 2; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PANCREATIC NEOPLASMS; PHENOTYPE; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; TIME FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; UP-REGULATION;

EID: 84944455351     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4494     Document Type: Article

References (41)

1. Ribas A, Tumeh PC. The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:4982-4984.
2. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, Xu Y, Fan J. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:971-979.
3. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:5064-5074.
4. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515:563-567.
5. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014; 11:509-24.
6. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, Smith DC, Taube JM, Wigginton JM, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32:1020-1030.
7. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369:122-133.
8. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, et al. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma. The New England journal of medicine. 2015; 372:2006-17.
9. Verstovsek S. Janus-activated kinase 2 inhibitors: a new era of targeted therapies providing significant clinical benefit for Philadelphia chromosome-negative myeloproliferative neoplasms. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011; 29:781-783.
10. Quintas-Cardama A, Kantarjian H, Cortes J, Verstovsek S. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature reviews Drug discovery. 2011; 10:127-140.
11. Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gonen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011; 121:2723-2735.
12. Hartman ZC, Poage GM, den Hollander P, Tsimelzon A, Hill J, Panupinthu N, Zhang Y, Mazumdar A, Hilsenbeck SG, Mills GB, Brown PH. Growth of triplenegative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res. 2013; 73:3470-3480.
13. Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Muller U, Murakami M, Radimerski T, Bentires-Alj M. JAK2/STAT5 inhibition circumvents resistance to PI3K/ mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell. 2012; 22:796-811.
14. Miller CP, Thorpe JD, Kortum AN, Coy CM, Cheng WY, Ou Yang TH, Anastassiou D, Beatty JD, Urban ND, Blau CA. JAK expression is associated with tumor-infiltrating lymphocytes and improved breast cancer outcomes: implications for evaluating JAK inhibitors. Cancer immunology research. 2014; 2:301-306.
15. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513:202-209.
16. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp MA. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood. 2010; 116:3268-3277.
17. Evers L, Perez-Mancera PA, Lenkiewicz E, Tang N, Aust D, Knosel T, Rummele P, Holley T, Kassner M, Aziz M, Ramanathan RK, Von Hoff DD, Yin H, Pilarsky C, Barrett MT. STAG2 is a clinically relevant tumor suppressor in pancreatic ductal adenocarcinoma. Genome medicine. 2014; 6:9.
18. Ruiz C, Lenkiewicz E, Evers L, Holley T, Robeson A, Kiefer J, Demeure MJ, Hollingsworth MA, Shen M, Prunkard D, Rabinovitch PS, Zellweger T, Mousses S, Trent JM, Carpten JD, Bubendorf L, et al. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci U S A. 2011; 108:12054-12059.
19. Ibrahim SF, van den Engh G. Flow cytometry and cell sorting. Adv Biochem Eng Biotechnol. 2007; 106:19-39.
20. Glogovac JK, Porter PL, Banker DE, Rabinovitch PS. Cytokeratin labeling of breast cancer cells extracted from paraffin-embedded tissue for bivariate flow cytometric analysis. Cytometry. 1996; 24:260-267.
21. Rabinovitch PS. DNA content histogram and cell-cycle analysis. Methods Cell Biol. 1994; 41:263-296.
22. Barrett MT, Sanchez CA, Prevo LJ, Wong DJ, Galipeau PC, Paulson TG, Rabinovitch PS, Reid BJ. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet. 1999; 22:106-109.
23. Maley CC, Galipeau PC, Finley JC, Wongsurawat VJ, Li X, Sanchez CA, Paulson TG, Blount PL, Risques RA, Rabinovitch PS, Reid BJ. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006; 38:468-473.
24. Holley T, Lenkiewicz E, Evers L, Tembe W, Ruiz C, Gsponer JR, Rentsch CA, Bubendorf L, Stapleton M, Amorese D, Legendre C, Cunliffe HE, McCullough AE, Pockaj B, Craig D, Carpten J, et al. Deep clonal profiling of formalin fixed paraffin embedded clinical samples. PLoS One. 2012; 7:e50586.
25. Lipson D, Aumann Y, Ben-Dor A, Linial N, Yakhini Z. Efficient calculation of interval scores for DNA copy number data analysis. J Comput Biol. 2006; 13:215-228.
26. Hao Y, Chapuy B, Monti S, Sun HH, Rodig SJ, Shipp MA. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res. 2014; 20:2674-2683.
27. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, et al. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma. N Engl J Med. 2015; 372:311-9.
28. Emens LA, Braiteh FS, Cassier P, DeLord J-P, Eder JP, Shen X, Xiao Y, Wang Y, Hedge PS, Chen DS, Krop I. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. San Antonio Breast Cancer Symposium. (San Antonio TX) 2014.
29. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Dolled-Filhart M, Emancipator K, Gonzalez E, Houp J, Pathiraja K, Karantza V, Iannone R, Gause C, Cheng J, et al. A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer. San Antonio Breast Cancer Symposium. (San Antonio TX) 2014.
30. Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL, Anders RA. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014; 20:5064-5074.
31. Wu J, Liu S, Liu G, Dombkowski A, Abrams J, Martin-Trevino R, Wicha MS, Ethier SP, Yang ZQ. Identification and functional analysis of 9p24 amplified genes in human breast cancer. Oncogene. 2012; 31:333-341.
32. Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sanchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gomez H, Horiuchi D, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014; 4:232-245.
33. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, Pitot HC, Hamid O, Bhatia S, Martins R, Eaton K, Chen S, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. The New England journal of medicine. 2012; 366:2455-2465.
34. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. The New England journal of medicine. 2012; 366:2443-2454.
35. Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM, Akcakanat A, Chawla A, Curran M, Hwu P, Sharma P, Litton JK, Molldrem JJ, et al. PD-L1 expression in triplenegative breast cancer. Cancer immunology research. 2014; 2:361-370.
36. Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. The Journal of pathology. 2014; 232:142-150.
37. Przybytkowski E, Lenkiewicz E, Barrett MT, Klein K, Nabavi S, Greenwood CM, Basik M. Chromosomebreakage genomic instability and chromothripsis in breast cancer. BMC Genomics. 2014; 15:579.
38. Stieber D, Golebiewska A, Evers L, Lenkiewicz E, Brons NH, Nicot N, Oudin A, Bougnaud S, Hertel F, Bjerkvig R, Vallar L, Barrett MT, Niclou SP. Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta neuropathologica. 2014; 127:203-219.
39. Galipeau PC, Li X, Blount PL, Maley CC, Sanchez CA, Odze RD, Ayub K, Rabinovitch PS, Vaughan TL, Reid BJ. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007; 4:e67.
40. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001; 96:3071-3083.
41. Piscuoglio S, Ng CK, Martelotto LG, Eberle CA, Cowell CF, Natrajan R, Bidard FC, De Mattos-Arruda L, Wilkerson PM, Mariani O, Vincent-Salomon A, Weigelt B, Reis-Filho JS. Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. Mol Oncol. 2014; 8:1588-1602.